MedTrace Logo

A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects

NCT01146327 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-04-19

No results posted yet for this study

Summary

PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110.

Conditions

  • Healthy

Interventions

DRUG

PF-04620110

Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.

DRUG

PF-04620110

Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.

DRUG

PF-04620110

Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.

DRUG

PF-04620110

Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.

DRUG

Placebo

Multiple oral doses of placebo will be given once daily for 2 weeks.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Belgium
  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01146327 on ClinicalTrials.gov